课题基金 / 基金详情

Molecular Besis of MeCP2 null-mutation Model Mouse and Gene Therapy

Molecular Besis of MeCP2 null-mutation Model Mouse and Gene Therapy
MeCP2无效突变小鼠模型的分子基础及基因治疗
批准号:
14370255
负责人:
MATSUISHI Toyojiro
金额:
$8.77万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2004

项目摘要

项目成果

MATSUISHI Toyojiro的其他基金

相似基金

相关文献

中文摘要
翻译
Rett综合征(RTT)是一种神经发育障碍,与甲基CpG结合蛋白2(MeCP2)突变有关。然而,目前尚不清楚基因型和表型之间的相关性。我们对219例RTT患者进行了MeCP2分析。在145名患者中发现了45种不同的突变(66.2%)。在经典RTT中,T158M是McCPZ最常见的错义突变,占19.1%,其次是R168X(14.8%)、R270X(13.0%)、R255X(9.6%)和R294X(6.1%)。R133C(33.3%)和R306C(23.3%)两个错义突变和R294X(13.3%)无义突变在30例不典型RTT患者中常见,包括保留的语音变体。已知的导致RTT样神经症状的半合子(-/y)雄性(-/y)小鼠的MeCP2缺失。我们用腺病毒载体将MeCP2基因导入纹状体,并与Ad.lacZ感染(对照)进行比较。39日龄和40日龄MeCP2-/Y小鼠,分别在4天和7天后进行多项行为学检查。每组7例。Ad.LacZ处理的小鼠运动能力进行性恶化,Ad.MeCP2处理的MeCP2-/Y小鼠的运动活动明显减弱。然后,我们利用成年雌性MeCP2-/+小鼠进行了在体腺病毒MeCP2基因导入双侧纹状体内前后的行为学研究。治疗后,大多数小鼠的运动能力明显改善。治疗效果在注射Ad.McCP-2后几周内达到显著水平,但在注射Ad.McCP-2后6周达到最大水平。所有表现为自我损伤的MeCP2-/+小鼠都通过McCP2基因治疗完全治愈了这些症状。综上所述,RTT是可逆的,在出生后和发病时,MeCP2的表达是可逆的,并且MeCP2在控制纹状体的运动和情绪方面起着至关重要的作用。
英文摘要
Rett syndrome (RTT) is a neurodevelopmental disorder, associated with mutations in the methyl-CpG-binding protein 2 (MeCP2). However, it is unknown the correlation between genotype and the phenotype yet.We performed MeCP2 analysis in 219 patients with RTT. A total of 45 different mutations were identified in 145 patients (66.2%). A missense mutation, T158M was the most common mutation of McCPZ, identified in 19.1%, followed by four nonsense mutations, R168X(14.8%), R270X(13.0%), R255X(9.6%), and R294X(6.1%) in classical RTT. Two missense mutation, R133C (33.3%), and R306C (23.3%), and a nonsense mutation, R294X (13.3%), were common in 30 patients with atypical RTT, including the preserved speech variant. Deletion of MeCP2 in hemizygous male (-/y) mice known to leads to RTT-like neurological symptoms. We transducted MeCP2 gene into the striaturn using adenoviral vector and compared to an infection of Ad.lacZ (control). The, MeCP2-/Y mice at 39 or 40 days old, several behavioral studies were performed 4 and 7 days later. (n=7 each group). The progressive deterioration of locomotion activity see in the Ad.LacZ-treated mice and there was significantly attenuated is the Ad.MeCP2-treated MeCP2-/Y mice. Then we performed the behavior studies before and after in vivo adenoviral MeCP2 gene transduction into the both striatum using the adult female MeCP2-/+ mice. The improvement of the impaired locomotors activity was clearly recognized in most of mice after the treatment. The therapeutic effects were met conspicuous within a few weeks, but then increased and reaches at the maximum level at 6 weeks after Ad.McCP 2 injection. All of the MeCP2 -/+ mice that had represented self-injuries were completely cured of these symptoms by McCP2 gene therapy. In conclusion, RTT is reversible by MeCP2 expression after birth and the onset, and MeCP2 plays essential roles in controlling locomotion and emotion in the striatum.
期刊论文(116)
专著(0)
科研奖励(0)
会议论文
松石豊次郎: "Rett症候群"小児内科. 35・増刊号. 804-807 (2003)
松石丰二郎:“雷特综合征”小儿内科 35/特刊 804-807 (2003)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Rett症候群
雷特综合征
DOI: --
发表时间: 2003
期刊: 小児内科 35・増刊号
影响因子: --
作者: [吉田 佐保, 松石豊次郎]
通讯作者: 松石豊次郎
Methyl-CpG bining protein 2 gene (MECP2) variations in Japanese patients with Rett syndrome : pathological mutations and polymorphisms.
日本 Rett 综合征患者的甲基 CpG 结合蛋白 2 基因 (MECP2) 变异:病理突变和多态性。
DOI: --
发表时间: 2005
期刊: Brain and Development 27
影响因子: --
作者: [Fukuda T, Yamashita Y,...Matsuishi T]
通讯作者: Yamashita Y,...Matsuishi T
Rett症候群 臨床徴候と遺伝子異常の相関画像,臨床生化学からみた病態
Rett综合征:临床体征与遗传异常、临床生化病理状况的相关图
DOI: --
发表时间: 2002
期刊: 脳と発達 34
影响因子: --
作者: [松石豊次郎, 山下裕史朗]
通讯作者: 山下裕史朗
共 36 条
    Research toward establishing comprehensive biological markers of pathophysiology in children with developmental disorders and early intervention.
    • 批准号:
      21591338
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.75万
    • 财政年份:
      2009
    • 负责人:
      MATSUISHI Toyojiro
    • 依托单位:
    Analysis of path physiology and treatment strategy in children with mild developmental disabilities by using functional brain imaging.
    • 批准号:
      18591172
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.37万
    • 财政年份:
      2006
    • 负责人:
      MATSUISHI Toyojiro
    • 依托单位:
    Genetic Study of Paroxysmal Kinesigenic Choreoathetosis
    • 批准号:
      10670770
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.11万
    • 财政年份:
      1998
    • 负责人:
      MATSUISHI Toyojiro
    • 依托单位:
    Linkage analysis of paroxysmal kinesigenic choreoatherosis
    • 批准号:
      08670930
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.02万
    • 财政年份:
      1996
    • 负责人:
      MATSUISHI Toyojiro
    • 依托单位:
    国内基金
    海外基金
    淫羊藿苷拮抗内源性甲醛神经毒性的作用及机制研究
    • 批准号:
      81102683
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      22.0万元
    • 批准年份:
      2011
    • 负责人:
      黎巍威
    • 依托单位:
    PICK1对心脏局部交感神经递质的平衡调控机制研究
    • 批准号:
      31000472
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      18.0万元
    • 批准年份:
      2010
    • 负责人:
      靳文英
    • 依托单位: